16 April 2026
Salt Capital and Proparco, the French Development finance institution, are pleased to announce their acquisition of The Namibian Oncology Centre (‘NOC’), a specialist cancer care provider in Namibia. For this transaction, Salt Capital partnered with Proparco through its FISEA Fund – Facility for investing in and supporting African business – that invests in high-impact funds and one of Salt Capital’s longstanding investors.
Founded by Namibian clinicians, healthcare professionals and local business people, NOC has played a pivotal role in advancing access to cancer diagnosis, treatment, and care in the country. The founders and selling shareholders dealt exclusively with Salt Capital to ensure the selection of a partner that will continue their proud legacy. The decision was based on shared values, cultural alignment, and a common commitment to improving cancer awareness and care outcomes in Namibia.
Salt Capital has an established track record of investing responsibly in Namibia’s private healthcare sector, including Rhino Park Private Hospital, Welwitschia Hospital and Erongo Radiology. With the addition of NOC, the firm continues its commitment to supporting high‑quality, ethical, and patient‑centred healthcare services in the country. Across its healthcare activities, Salt Capital places a strong emphasis on governance, clinical independence, and regulatory compliance, ensuring that patient care and ethical medical practice remain paramount.
NOC will continue to operate as an independent specialist provider, under the leadership of its existing management team, with Stephanie Quarmby continuing as Managing Director. Salt Capital and Proparco’s role will be that of a long-term, supportive shareholder, focused on strengthening governance, sustainability, and healthcare standards, while preserving the Centre’s clinical autonomy and culture of care.
Beyond clinical services, the investment reflects a broader commitment to raising awareness of cancer in Namibia, supporting early detection, patient education, and contributing to the country’s growing reputation as a destination for quality healthcare and medical tourism within the region. Furthermore, NOC is proud of its partnership with the government public health sector in providing affordable cancer care to bridge the rural-urban quality gap.
Following the NOC transaction, Salt Capital’s healthcare portfolio represents the largest private capital investment in healthcare in Namibia; a responsibility not taken lightly by the members of the firm.
Jan Bosch, Managing Partner of Salt Capital, commented:
“The Namibian Oncology Centre plays a critical role in the country’s healthcare ecosystem. We are honoured to have been chosen by the founders as the new long-term partners of NOC, and we approach this investment with humility and responsibility. Our focus is on supporting the Centre’s mission, strengthening healthcare standards, and contributing meaningfully to cancer awareness and access to care in Namibia.”
Johann Choux, Regional Director – Southern Africa and Indian Ocean at Proparco commented:
“By supporting The Namibian Oncology Centre, we are contributing to expanding access to high-quality oncology care and strengthening cancer awareness. This project aligns with our 2023–2027 strategy: partnering with local players to deliver concrete impact, particularly by reducing inequalities in access to essential services, while supporting the sustainability and quality of care in developing countries.”
Jacques Maree, outgoing Chairman and exiting shareholder of NOC, said:
“When the Namibian Oncology Centre was founded, our objective was always to build an institution that serves patients with dignity, compassion, and excellence. In Salt Capital and Proparco, we found a partner that respects those principles and understands the responsibility that comes with investing in healthcare. I am confident NOC is well positioned for the future in the capable hands of Salt Capital and Proparco.”
Stephanie Quarmby added:
“NOC’s clinical team and management look forward to continuing our work with the support of Salt Capital and Proparco. This partnership allows us to remain true to our purpose, while reinforcing governance, long-term sustainability, and our role in advancing cancer awareness and care in Namibia.”
END
About Salt Capital
Founded in 2012, Salt Capital is a private equity investment firm focused on growth capital investments in the SADC region. Salt Capital’s new fund, Salt Equity I, is anchored by a diverse and blue-chip international investor base and has a mandate to invest in SME businesses with a particular focus on consumer facing sectors. For more information, visit www.saltcapital.com or follow on LinkedIn
About Proparco
Proparco is France’s development finance institution dedicated to the private sector and part of the French Development Agency (AFD) Group. For over 50 years, it has supported sustainable economic, social, and environmental development across Africa, Asia, Latin America, Eurasia, and the Middle East, by financing companies and financial institutions in more than 115 countries.
Its activities focus on key sectors including renewable energy, infrastructure, agribusiness, healthcare, and education. Proparco offers a range of financial solutions – loans, guarantees, and investments – as well as technical assistance through its Propulse program. Its subsidiary Digital Africa supports early-stage African tech startups.
With 26 local offices worldwide, Proparco works closely with its partners to build a more just and sustainable world.
More information: www.proparco.fr/en | LinkedIn: @Proparco
About The Namibian Oncology Centre
The Namibian Oncology Centre is Namibia’s first comprehensive private cancer care facility, with sites in Windhoek (Eros and Khomasdal), Swakopmund, and a fourth practice opening in Ongwediva in mid-2026. NOC offers radiation therapy, medical oncology, haematology oncology, stem cell transplantation, prostate brachytherapy, and a full range of patient support services. The centre operates Namibia’s only two linear accelerators and a 16-bed oncology ward including a specialist isolation unit.
For more information, visit www.namoncology.com